Cutaneous side effects associated with interleukin 2 administration for metastatic melanoma
Autor: | Jean Revuz, Janine Wechsler, Olivier Chosidow, Marie-Claude Lescs, Pierre Wolkenstein, Maud Brandely, Marie-Françoise Avril, Jean-Claude Guillaume |
---|---|
Rok vydání: | 1993 |
Předmět: |
Interleukin 2
Adult Male medicine.medical_specialty Pathology Skin Neoplasms Erythema medicine.medical_treatment Biopsy Dermatology Peripheral blood mononuclear cell Immunoenzyme Techniques Immunophenotyping medicine Humans IL-2 receptor Prospective Studies skin and connective tissue diseases Infusions Intravenous Melanoma Aged Retrospective Studies medicine.diagnostic_test business.industry Middle Aged Recombinant Proteins Cytokine Interleukin-2 Histopathology Female Drug Eruptions medicine.symptom business medicine.drug |
Zdroj: | Journal of the American Academy of Dermatology. 28(1) |
ISSN: | 0190-9622 |
Popis: | Background: Cutaneous changes associated with recombinant interleukin 2 (r IL-2) administration are frequent but have been rarely studied in a large series. Objective: We analyzed these clinical, microscopic, and immunologic changes. Methods: Patients with metastatic melanoma treated with r IL-2 were studied. The eruption was scored as mild or severe. Biopsy specimens were obtained for histopathology, ultrastructural analysis, and immunophenotyping. Chi-square and t tests were used for statistics. Results: Twenty-five patients were included. Eruptions were observed in 56 of 78 cycles (72%); 53 were mild with a burning pruriginous erythema, and 3 were severe with urticaria, necrotic lesions, and blisters. Regression was constant without sequelae. Pathologic changes were mild with a mononuclear cell infiltrate of activated helper T phenotype, expressing LFA-1. Keratinocytes and endothelial cells displayed intercellular adhesion molecule-1 and HLA-DR. Cells rarely expressed CD25. Conclusion: Administration of r IL-2 triggers non-treatment-limiting cutaneous inflammation. |
Databáze: | OpenAIRE |
Externí odkaz: |